
Borek Vojtesek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/571599/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	An immunochemical analysis of the human nuclear phosphoprotein p53. Journal of Immunological Methods, 1992, 151, 237-244.	1.4	524
2	Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in <i>Escherichia</i> coli. Journal of Cell Science, 1992, 101, 183-190.	2.0	298
3	The role of the 3'Âuntranslated region in post-transcriptional regulation of protein expression in mammalian cells RNA Biology, 2012, 9, 563-576.	3.1	297
4	Differential expression of p63 isoforms in normal tissues and neoplastic cells. Journal of Pathology, 2002, 198, 417-427.	4.5	246
5	STAT3, stem cells, cancer stem cells and p63. Cellular and Molecular Biology Letters, 2018, 23, 12.	7.0	188
6	C-terminal phosphorylation of Hsp70 and Hsp90 regulates alternate binding to co-chaperones CHIP and HOP to determine cellular protein folding/degradation balances. Oncogene, 2013, 32, 3101-3110.	5.9	171
7	Discriminating functional and non-functional p53 in human tumours by p53 and MDM2 immunohistochemistry. Journal of Pathology, 2005, 207, 251-259.	4.5	128
8	Emerging roles for the pro-oncogenic anterior gradient-2 in cancer development. Oncogene, 2013, 32, 2499-2509.	5.9	126
9	Up-regulation of Fas (CD95) in human p53wild-type cancer cells treated with ionizing radiation. , 1997, 73, 757-762.		109
10	Anterior gradient 2: A novel player in tumor cell biology. Cancer Letters, 2011, 304, 1-7.	7.2	109
11	Biomarker Discovery in Low-Grade Breast Cancer Using Isobaric Stable Isotope Tags and Two-Dimensional Liquid Chromatography-Tandem Mass Spectrometry (iTRAQ-2DLC-MS/MS) Based Quantitative Proteomic Analysis. Journal of Proteome Research, 2009, 8, 362-373.	3.7	98
12	Immunohtstochemical analysis of the p53 oncoprotein on paraffin sections using a series of novel monoclonal antibodies. Journal of Pathology, 1993, 169, 27-34.	4.5	95
13	The pro-metastatic protein anterior gradient-2 predicts poor prognosis in tamoxifen-treated breast cancers. Oncogene, 2010, 29, 4838-4847.	5.9	87
14	Stoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription. Journal of Biological Chemistry, 2001, 276, 4699-4708.	3.4	84
15	Tumor suppressor protein p53 binds preferentially to supercoiled DNA. Oncogene, 1997, 15, 2201-2209.	5.9	82
16	The role of P63 in cancer, stem cells and cancer stem cells. Cellular and Molecular Biology Letters, 2011, 16, 296-327.	7.0	72
17	Conformational changes in p53 analysed using new antibodies to the core DNA binding domain of the protein. Oncogene, 1995, 10, 389-93.	5.9	67
18	Effect of transition metals on binding of p53 protein to supercoiled DNA and to consensus sequence in DNA fragments. Oncogene, 1999, 18, 3617-3625.	5.9	63

#	Article	IF	CITATIONS
19	Cross-talk between HIF and p53 as mediators of molecular responses to physiological and genotoxic stresses. Molecular Cancer, 2013, 12, 93.	19.2	63
20	Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment. Journal of Cellular and Molecular Medicine, 2009, 13, 440-453.	3.6	60
21	Role of tumor suppressor p53 domains in selective binding to supercoiled DNA. Nucleic Acids Research, 2002, 30, 4966-4974.	14.5	57
22	New ELISA technique for analysis of p53 protein/DNA binding properties. Journal of Immunological Methods, 2002, 267, 227-235.	1.4	56
23	Hsp90 Is Essential for Restoring Cellular Functions of Temperature-sensitive p53 Mutant Protein but Not for Stabilization and Activation of Wild-type p53. Journal of Biological Chemistry, 2005, 280, 6682-6691.	3.4	54
24	A global analysis of the complex landscape of isoforms and regulatory networks of p63 in human cells and tissues. BMC Genomics, 2015, 16, 584.	2.8	52
25	p53 derived from human tumour cell lines and containing distinct point mutations can be activated to bind its consensus target sequence. Oncogene, 1995, 10, 881-90.	5.9	48
26	A Divergent Substrate-Binding Loop within the Pro-oncogenic Protein Anterior Gradient-2 Forms a Docking Site for Reptin. Journal of Molecular Biology, 2010, 404, 418-438.	4.2	47
27	Mechanisms of anterior gradient-2 regulation and function in cancer. Seminars in Cancer Biology, 2015, 33, 16-24.	9.6	44
28	Potent induction of wild-type p53-dependent transcription in tumour cells by a synthetic inhibitor of cyclin-dependent kinases. Cellular and Molecular Life Sciences, 2001, 58, 1333-1339.	5.4	43
29	AGR2 oncoprotein inhibits p38 MAPK and p53 activation through a DUSP10â€mediated regulatory pathway. Molecular Oncology, 2016, 10, 652-662.	4.6	43
30	The Assembly and Intermolecular Properties of the Hsp70-Tomm34-Hsp90 Molecular Chaperone Complex. Journal of Biological Chemistry, 2014, 289, 9887-9901.	3.4	42
31	On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. Philosophical Transactions of the Royal Society B: Biological Sciences, 1995, 347, 83-87.	4.0	41
32	Anterior Gradient-3: A novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models. Journal of Immunological Methods, 2012, 378, 20-32.	1.4	41
33	Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer. Cellular and Molecular Biology Letters, 2012, 17, 446-58.	7.0	41
34	The role of AGR2 and AGR3 in cancer: Similar but not identical. European Journal of Cell Biology, 2015, 94, 139-147.	3.6	41
35	The p53 knowledgebase: an integrated information resource for p53 research. Oncogene, 2007, 26, 1517-1521.	5.9	40
36	Investigations of the supercoil-selective DNA binding of wild type p53 suggest a novel mechanism for controlling p53 function. FEBS Journal, 2004, 271, 3865-3876.	0.2	37

#	Article	IF	CITATIONS
37	Surface-enhanced laser desorption/ionization time-of-flight proteomic profiling of breast carcinomas identifies clinicopathologically relevant groups of patients similar to previously defined clusters from cDNA expression. Breast Cancer Research, 2008, 10, R48.	5.0	36
38	Human Stress-inducible Hsp70 Has a High Propensity to Form ATP-dependent Antiparallel Dimers That Are Differentially Regulated by Cochaperone Binding*. Molecular and Cellular Proteomics, 2019, 18, 320-337.	3.8	35
39	Activation of the DNA-binding ability of latent p53 protein by protein kinase C is abolished by protein kinase CK2. Biochemical Journal, 2004, 378, 939-947.	3.7	33
40	ΔNp63 transcriptionally regulates ATM to control p53 Serine-15 phosphorylation. Molecular Cancer, 2010, 9, 195.	19.2	33
41	Suppression of AGR2 in a TGF-β-induced Smad regulatory pathway mediates epithelial-mesenchymal transition. BMC Cancer, 2017, 17, 546.	2.6	30
42	Specific Modulation of p53 Binding to Consensus Sequence within Supercoiled DNA by Monoclonal Antibodies. Biochemical and Biophysical Research Communications, 2000, 267, 934-939.	2.1	29
43	Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2013, 463, 415-425.	2.8	29
44	AGR2 Predicts Tamoxifen Resistance in Postmenopausal Breast Cancer Patients. Disease Markers, 2013, 35, 207-212.	1.3	29
45	Identification of a second Nutlin-3 responsive interaction site in the N-terminal domain of MDM2 using hydrogen/deuterium exchange mass spectrometry. Proteomics, 2013, 13, 2512-2525.	2.2	28
46	<i>MDM2</i> SNP309 Does Not Associate with Elevated MDM2 Protein Expression or Breast Cancer Risk. Oncology, 2008, 74, 84-87.	1.9	27
47	Restoring wild-type conformation and DNA-binding activity of mutant p53 is insufficient for restoration of transcriptional activity. Biochemical and Biophysical Research Communications, 2006, 351, 499-506.	2.1	26
48	The new platinum(IV) derivative LA-12 shows stronger inhibitory effect on Hsp90 function compared to cisplatin. Molecular Cancer, 2010, 9, 147.	19.2	26
49	The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histology and Histopathology, 2015, 30, 503-21.	0.7	26
50	Impaired Pre-mRNA Processing and Altered Architecture of 3' Untranslated Regions Contribute to the Development of Human Disorders. International Journal of Molecular Sciences, 2013, 14, 15681-15694.	4.1	25
51	Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncology Reports, 2014, 32, 1695-1702.	2.6	25
52	Identification of an AKT-dependent signalling pathway that mediates tamoxifen-dependent induction of the pro-metastatic protein anterior gradient-2. Cancer Letters, 2013, 333, 187-193.	7.2	24
53	Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them?. Cellular and Molecular Biology Letters, 2021, 26, 53.	7.0	24
54	The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo. Proteome Science, 2011, 9, 68.	1.7	23

#	Article	IF	CITATIONS
55	Recognition of DNA modified by antitumor cisplatin by "latent―and "active―protein p53. Biochemical Pharmacology, 2003, 65, 1305-1316.	4.4	22
56	CK2-site Phosphorylation of p53 is Induced in ΔNp63 Expressing Basal Stem Cells in UVB Irradiated Human Skin. Cell Cycle, 2006, 5, 2489-2494.	2.6	22
57	ΔNp63 activates EGFR signaling to induce loss of adhesion in triple-negative basal-like breast cancer cells. Breast Cancer Research and Treatment, 2017, 163, 475-484.	2.5	22
58	Precise characterisation of monoclonal antibodies to the C-terminal region of p53 protein using the PEPSCAN ELISA technique and a new non-radioactive gel shift assay. Journal of Immunological Methods, 2000, 237, 51-64.	1.4	21
59	Intronic polymorphisms in TP53 indicate lymph node metastasis in breast cancer. Oncology Reports, 2009, 22, 1205-11.	2.6	20
60	Intact protein profiling in breast cancer biomarker discovery: Protein identification issue and the solutions based on 3D protein separation, bottom-up and top-down mass spectrometry. Proteomics, 2013, 13, 1053-1058.	2.2	20
61	Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status. Journal of Pathology, 2014, 233, 238-246.	4.5	20
62	Differential expression of anterior gradient protein 3 in intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Experimental and Molecular Pathology, 2014, 96, 375-381.	2.1	20
63	The novel platinum(IV) complex LA-12 induces p53 and p53/47 responses that differ from the related drug, cisplatin. Anti-Cancer Drugs, 2008, 19, 369-379.	1.4	19
64	TAp63gamma is required for the late stages of myogenesis. Cell Cycle, 2015, 14, 894-901.	2.6	19
65	Novel Entropically Driven Conformation-specific Interactions with Tomm34 Protein Modulate Hsp70 Protein Folding and ATPase Activities. Molecular and Cellular Proteomics, 2016, 15, 1710-1727.	3.8	19
66	The effects of IFITM1 and IFITM3 gene deletion on IFNÎ ³ stimulated protein synthesis. Cellular Signalling, 2019, 60, 39-56.	3.6	19
67	Development of a fluorescent monoclonal antibodyâ€based assay to measure the allosteric effects of synthetic peptides on selfâ€oligomerization of AGR2 protein. Protein Science, 2013, 22, 1266-1278.	7.6	18
68	Effect of His6-tagging of anterior gradient 2 protein on its electro-oxidation. Electrochimica Acta, 2014, 150, 218-222.	5.2	18
69	Tamoxifen-Dependent Induction of <i>AGR2</i> Is Associated with Increased Aggressiveness of Endometrial Cancer Cells. Cancer Investigation, 2017, 35, 313-324.	1.3	18
70	Surface-Enhanced Laser Desorption Ionization/Time-of-Flight Mass Spectrometry Reveals Significant Artifacts in Serum Obtained from Clot Activator–Containing Collection Devices. Clinical Chemistry, 2006, 52, 2115-2116.	3.2	17
71	Anterior gradient protein 3 is associated with less aggressive tumors and better outcome of breast cancer patients. OncoTargets and Therapy, 2015, 8, 1523.	2.0	17
72	ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells. BMC Cancer, 2016, 16, 782.	2.6	17

#	Article	IF	CITATIONS
73	AGR2 associates with HER2 expression predicting poor outcome in subset of estrogen receptor negative breast cancer patients. Experimental and Molecular Pathology, 2017, 102, 280-283.	2.1	17
74	Quantitative Shotgun Proteomics Unveils Candidate Novel Esophageal Adenocarcinoma (EAC)-specific Proteins. Molecular and Cellular Proteomics, 2017, 16, 1138-1150.	3.8	17
75	p63 isoforms in triple-negative breast cancer: ΔNp63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2018, 472, 351-359.	2.8	17
76	The Sequence-specific Peptide-binding Activity of the Protein Sulfide Isomerase AGR2 Directs Its Stable Binding to the Oncogenic Receptor EpCAM. Molecular and Cellular Proteomics, 2018, 17, 737-763.	3.8	16
77	The effect of cellular environment and p53 status on the mode of action of the platinum derivative LA-12. Investigational New Drugs, 2010, 28, 445-453.	2.6	15
78	Rearrangement of mitochondrial pyruvate dehydrogenase subunit dihydrolipoamide dehydrogenase protein–protein interactions by the MDM2 ligand nutlinâ€3. Proteomics, 2016, 16, 2327-2344.	2.2	14
79	The role of miR-409-3p in regulation of HPV16/18-E6 mRNA in human cervical high-grade squamous intraepithelial lesions. Antiviral Research, 2019, 163, 185-192.	4.1	14
80	The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. Cellular and Molecular Biology Letters, 2020, 25, 41.	7.0	14
81	The Role of IFITM Proteins in Tick-Borne Encephalitis Virus Infection. Journal of Virology, 2022, 96, JVI0113021.	3.4	14
82	â^†Np63/p40 correlates with the location and phenotype of basal/mesenchymal cancer stemâ€ l ike cells in human ER ⁺ and HER2 ⁺ breast cancers. Journal of Pathology: Clinical Research, 2020, 6, 83-93.	3.0	13
83	What do we need to know and understand about p53 to improve its clinical value?. Journal of Pathology, 2021, 254, 443-453.	4.5	13
84	The cell type-specific effect of TAp73 isoforms on the cell cycle and apoptosis. Cellular and Molecular Biology Letters, 2008, 13, 404-20.	7.0	12
85	Regulation of AGR2 expression via 3'UTR shortening. Experimental Cell Research, 2017, 356, 40-47.	2.6	12
86	Tomm34 is commonly expressed in epithelial ovarian cancer and associates with tumour type and high FIGO stage. Journal of Ovarian Research, 2019, 12, 30.	3.0	12
87	The interaction of the mitochondrial protein importer TOMM34 with HSP70 is regulated by TOMM34 phosphorylation and binding to 14-3-3 adaptors. Journal of Biological Chemistry, 2020, 295, 8928-8944.	3.4	12
88	Switching p53-dependent growth arrest to apoptosis via the inhibition of DNA damage-activated kinases. Cellular and Molecular Biology Letters, 2010, 15, 473-84.	7.0	11
89	Inhibition of Post-Transcriptional RNA Processing by CDK Inhibitors and Its Implication in Anti-Viral Therapy. PLoS ONE, 2014, 9, e89228.	2.5	11
90	TAp63 and ΔNp63 (p40) in prostate adenocarcinomas: ΔNp63 associates with a basal-like cancer stem cell population but not with metastasis. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 478, 627-636.	2.8	10

#	Article	lF	CITATIONS
91	TAp73Î ² Can Promote Hepatocellular Carcinoma Dedifferentiation. Cancers, 2021, 13, 783.	3.7	10
92	Anterior Gradient 2 and Mucin 4 Expression Mirrors Tumor Cell Differentiation in Pancreatic Adenocarcinomas, But Aberrant Anterior Gradient 2 Expression Predicts Worse Patient Outcome in Poorly Differentiated Tumors. Pancreas, 2014, 43, 75-81.	1.1	9
93	The Elephant Evolved p53 Isoforms that Escape MDM2-Mediated Repression and Cancer. Molecular Biology and Evolution, 2022, 39, .	8.9	9
94	Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition. PLoS ONE, 2018, 13, e0202758.	2.5	7
95	A Cyclic Pentamethinium Salt Induces Cancer Cell Cytotoxicity through Mitochondrial Disintegration and Metabolic Collapse. International Journal of Molecular Sciences, 2019, 20, 4208.	4.1	7
96	An Ultrasensitive Biosensor for Detection of Femtogram Levels of the Cancer Antigen AGR2 Using Monoclonal Antibody Modified Screen-Printed Gold Electrodes. Biosensors, 2021, 11, 184.	4.7	7
97	Targeting Oncogenic Pathways in the Era of Personalized Oncology: A Systemic Analysis Reveals Highly Mutated Signaling Pathways in Cancer Patients and Potential Therapeutic Targets. Cancers, 2022, 14, 664.	3.7	7
98	AGR2 silencing contributes to metformin‑dependent sensitization of colorectal cancer cells to chemotherapy. Oncology Letters, 2019, 18, 4964-4973.	1.8	6
99	A "spindle and thread―mechanism unblocks p53 translation by modulating N-terminal disorder. Structure, 2022, 30, 733-742.e7.	3.3	5
100	The effects of p53 gene inactivation on mutant proteome expression in a human melanoma cell model. Biochimica Et Biophysica Acta - General Subjects, 2020, 1864, 129722.	2.4	4
101	Anticancer pentamethinium salt is a potent photosensitizer inducing mitochondrial disintegration and apoptosis upon red light illumination. Journal of Photochemistry and Photobiology B: Biology, 2020, 209, 111939.	3.8	4
102	Kinomics platform using GBM tissue identifies BTK as being associated with higher patient survival. Life Science Alliance, 2021, 4, e202101054.	2.8	4
103	Identifying pathways regulating the oncogenic p53 family member ΔNp63 provides therapeutic avenues for squamous cell carcinoma. Cellular and Molecular Biology Letters, 2022, 27, 18.	7.0	4
104	Allosteric changes in HDM2 by the ATM phosphomimetic S395D mutation: implications on HDM2 function. Biochemical Journal, 2019, 476, 3401-3411.	3.7	3
105	DNA Demethylation Switches Oncogenic ΔNp63 to Tumor Suppressive TAp63 in Squamous Cell Carcinoma. Frontiers in Oncology, 0, 12, .	2.8	2
106	An integrated DNA and RNA variant detector identifies a highly conserved three base exon in the <i>MAP4K5</i> kinase locus. RNA Biology, 2021, 18, 2556-2575.	3.1	1